In the training group, significant correlations were identified between OS in glioma patients and the following factors: SCAMP5 gene expression, PRS type, age, IDH mutation status, 1p/19q co-deletion status, radiotherapy, temozolomide (TMZ) treatment, and WHO grade. Here, SCAMP5 is linked to central nervous system cancer.